SI2041138T1 - Pirolotriazin kinazni inhibitorji - Google Patents

Pirolotriazin kinazni inhibitorji

Info

Publication number: SI2041138T1
Authority: SI; Slovenia
Prior art keywords: kinase inhibitors; pyrrolotriazine kinase; pyrrolotriazine; inhibitors; kinase
Prior art date: 2006-07-07

Application number

SI200731488T

Other languages

English (en)

Inventor

Harold Mastalerz

Mark D. Wittman

Kurt Zimmermann

Mark G. Saulnier

Upender Velaparthi

Dolatrai M. Vyas

Guifen Zhang

Walter Lewis Johnson

David B. Frennesson

Xiaopeng Sang

Peiying Liu

David R. Langley

Original Assignee

Bristol-Myers Squibb Company

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-07-07

Filing date

2007-07-03

Publication date

2014-08-29

2007-07-03 Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company

2014-08-29 Publication of SI2041138T1 publication Critical patent/SI2041138T1/sl

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Diabetes (AREA)
Hematology (AREA)
Biomedical Technology (AREA)
Immunology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Dermatology (AREA)
Obesity (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Oncology (AREA)
Orthopedic Medicine & Surgery (AREA)
Rheumatology (AREA)
Physical Education & Sports Medicine (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

SI200731488T 2006-07-07 2007-07-03 Pirolotriazin kinazni inhibitorji SI2041138T1 (sl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US81917106P	2006-07-07	2006-07-07
EP07799265.9A EP2041138B1 (en)	2006-07-07	2007-07-03	Pyrrolotriazine kinase inhibitors
PCT/US2007/072697 WO2008005956A2 (en)	2006-07-07	2007-07-03	Pyrrolotriazine kinase inhibitors

Publications (1)

Publication Number	Publication Date
SI2041138T1 true SI2041138T1 (sl)	2014-08-29

Family

ID=38671050

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SI200731488T SI2041138T1 (sl)	2006-07-07	2007-07-03	Pirolotriazin kinazni inhibitorji

Country Status (26)

Country	Link
US (4)	US7534792B2 (sl)
EP (1)	EP2041138B1 (sl)
JP (1)	JP5185930B2 (sl)
KR (1)	KR101443400B1 (sl)
CN (1)	CN101511835B (sl)
AR (1)	AR061873A1 (sl)
AU (1)	AU2007269163B2 (sl)
BR (1)	BRPI0714359A2 (sl)
CA (1)	CA2657594C (sl)
CL (1)	CL2007001995A1 (sl)
CO (1)	CO6220940A2 (sl)
DK (1)	DK2041138T3 (sl)
EA (1)	EA018322B1 (sl)
ES (1)	ES2493566T3 (sl)
HR (1)	HRP20140688T1 (sl)
IL (1)	IL196033A0 (sl)
MX (1)	MX2008016517A (sl)
NO (1)	NO342385B1 (sl)
NZ (1)	NZ574189A (sl)
PE (1)	PE20080677A1 (sl)
PL (1)	PL2041138T3 (sl)
PT (1)	PT2041138E (sl)
SI (1)	SI2041138T1 (sl)
TW (1)	TWI393722B (sl)
WO (1)	WO2008005956A2 (sl)
ZA (1)	ZA200900109B (sl)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
UA95298C2 (ru) *	2006-07-07	2011-07-25	Бьёрингер Ингельхайм Интернациональ Гмбх	Фенилзамещенные гетероарильные производные и их применение в качестве противоопухолевых средств
JP5185930B2 (ja) *	2006-07-07	2013-04-17	ブリストル−マイヤーズスクイブカンパニー	ピロロトリアジンキナーゼ阻害剤
EP2134716A1 (en) *	2007-04-18	2009-12-23	Bristol-Myers Squibb Company	Pyrrolotriazine kinase inhibitors
EP2559771A3 (en) *	2007-05-17	2013-06-12	Bristol-Myers Squibb Company	Biomarkers and methods for determining sensitivity to insulin growth factor-1 receptor modulators
CA2692379A1 (en) *	2007-07-02	2009-01-08	Boehringer Ingelheim International Gmbh	Antiproliferative compounds based on 5-membered heterocycles
CL2008001943A1 (es) *	2007-07-02	2009-09-11	Boehringer Ingelheim Int	Compuestos derivados de fenil-triazol, inhibidores de enzimas de señales especificas que participan del control de la proliferacion celular; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cancer, infecciones, enfermedades inflamatorias y autoinmunes.
CN102015719A (zh) *	2008-03-06	2011-04-13	百时美施贵宝公司	吡咯并三嗪激酶抑制剂
US8778929B2 (en)	2008-09-29	2014-07-15	Boehringer Ingelheim International Gmbh	Substituted heteroaryl inhibitors of B-RAF
JP5592890B2 (ja) *	2008-10-08	2014-09-17	ブリストル−マイヤーズスクイブカンパニー	ピロロトリアジンキナーゼ阻害剤
TW201035100A (en)	2008-12-19	2010-10-01	Cephalon Inc	Pyrrolotriazines as ALK and JAK2 inhibitors
EP2494070A2 (en)	2009-10-30	2012-09-05	Bristol-Myers Squibb Company	Methods for treating cancer in patients having igf-1r inhibitor resistance
WO2011083391A2 (en)	2010-01-05	2011-07-14	Pfizer Inc.	Biomarkers for anti-igf-ir cancer therapy
WO2011097331A1 (en)	2010-02-03	2011-08-11	Bristol-Myers Squibb Company	Crystalline forms of (s)-1-(4-(5-cyclopropyl-1h-pyrazol-3- ylamino)pyrrolo [1,2-f] [1,2,4] triazin-2-yl)-n-(6-fluoropyridin- 3-yl)-2-methylpyrrolidine-2-carboxamide
JP5093527B2 (ja) *	2010-02-10	2012-12-12	日本電気株式会社	複合光導波路、波長可変フィルタ、波長可変レーザ、および光集積回路
WO2011117382A1 (en)	2010-03-26	2011-09-29	Boehringer Ingelheim International Gmbh	Pyridyltriazoles
JP5871896B2 (ja)	2010-03-26	2016-03-01	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	Ｂ−ｒａｆキナーゼインヒビター
JP5752232B2 (ja)	2010-03-31	2015-07-22	ブリストル−マイヤーズスクイブカンパニーＢｒｉｓｔｏｌ−ＭｙｅｒｓＳｑｕｉｂｂＣｏｍｐａｎｙ	プロテインキナーゼ阻害剤としての置換ピロロトリアジン化合物
US8710055B2 (en)	2010-12-21	2014-04-29	Boehringer Ingelheim International Gmbh	Triazolylphenyl sulfonamides as serine/threonine kinase inhibitors
CN102584828B (zh) *	2011-01-14	2016-01-27	上海艾力斯医药科技有限公司	吡咯烷[3，4-d]嘧啶衍生物、制备方法及其应用
WO2013056069A1 (en)	2011-10-13	2013-04-18	Bristol-Myers Squibb Company	Methods for selecting and treating cancer in patients with igf-1r/ir inhibitors
BR112014009108A2 (pt)	2011-10-25	2017-04-18	Shionogi & Co	derivado heterocíclico tendo atividade antagonista de receptor de pgd2
CN103450204B (zh)	2012-05-31	2016-08-17	中国科学院上海药物研究所	吡咯[2，1-f][1，2，4]并三嗪类化合物，其制备方法及用途
US9724352B2 (en)	2012-05-31	2017-08-08	Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences	Pyrrolo[2,1-F[1,2,4]triazine compounds, preparation methods and applications thereof
US9499519B2 (en)	2012-12-26	2016-11-22	Medivation Technologies, Inc.	Fused pyrimidine compounds and use thereof
US9050345B2 (en)	2013-03-11	2015-06-09	Bristol-Myers Squibb Company	Pyrrolotriazines as potassium ion channel inhibitors
US9499522B2 (en)	2013-03-15	2016-11-22	Blueprint Medicines Corporation	Compositions useful for treating disorders related to kit
US9334263B2 (en)	2013-10-17	2016-05-10	Blueprint Medicines Corporation	Compositions useful for treating disorders related to kit
SG11201602937UA (en)	2013-10-17	2016-05-30	Blueprint Medicines Corp	Compositions useful for treating disorders related to kit
WO2015081783A1 (zh) *	2013-12-06	2015-06-11	江苏奥赛康药业股份有限公司	吡咯并[2,1-f][1,2,4]三嗪类衍生物及其制备方法和用途
WO2015126808A2 (en) *	2014-02-18	2015-08-27	Baldwin John J	Hbv assay
TWI672141B (zh)	2014-02-20	2019-09-21	美商醫科泰生技	投予ｒｏｓ１突變癌細胞之分子
CN104974163B (zh) *	2014-04-14	2017-11-07	广东东阳光药业有限公司	取代的杂芳基化合物及其组合物和用途
US9688680B2 (en)	2014-08-04	2017-06-27	Blueprint Medicines Corporation	Compositions useful for treating disorders related to kit
KR102595599B1 (ko)	2014-12-02	2023-11-02	이그니타, 인코포레이티드	신경모세포종의 치료를 위한 병용
AU2016297754A1 (en) *	2015-07-24	2018-02-15	Blueprint Medicines Corporation	Compounds useful for treating disorders related to KIT and PDGFR
EP3389645A4 (en)	2015-12-18	2019-12-18	Ignyta, Inc.	COMBINATIONS FOR TREATING CANCER
EP3475281A1 (en) *	2016-06-23	2019-05-01	H. Hoffnabb-La Roche Ag	Novel [1,2,31triazolo[4,5-d]pyrimidine derivatives
TW201837026A (zh)	2017-01-10	2018-10-16	德商拜耳廠股份有限公司	作為除害劑之雜環衍生物（二）
UY37556A (es)	2017-01-10	2018-07-31	Bayer Ag	Derivados heterocíclicos como pesticidas
WO2018183712A1 (en)	2017-03-31	2018-10-04	Blueprint Medicines Corporation	Pyrrolo[1,2-b]pyridazine compounds and compositions useful for treating disorders related to kit and pdgfr
EP3392267A1 (en)	2017-04-18	2018-10-24	Myr GmbH	Therapy of atherosclerosis, primary biliary cirrhosis and nrlp3 inflammasome-associated disease by htcp inhibitors
AR112027A1 (es) *	2017-06-15	2019-09-11	Biocryst Pharm Inc	Inhibidores de alk 2 quinasa que contienen imidazol
WO2019018570A1 (en)	2017-07-19	2019-01-24	Ignyta, Inc.	PHARMACEUTICAL COMPOSITIONS CONTAINING ENTRECTINIB
JP7311498B2 (ja)	2017-10-17	2023-07-19	イグナイタインコーポレイテッド	薬学的組成物および剤形
KR102875260B1 (ko)	2019-04-12	2025-10-23	블루프린트 메디신즈 코포레이션	Kit- 및 pdgfra 매개성 질환을 치료하기 위한 피롤로트리아진 유도체
EP3856341B1 (en)	2019-04-12	2023-09-06	Blueprint Medicines Corporation	Crystalline forms of (s)-1-(4-fluorophenyl)-1-(2-(4-(6-(1-methyl-1h-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)piperazinyl)-pyrimidin-5-yl)ethan-1-amine and methods of making
EP3985005A4 (en) *	2019-06-14	2023-07-19	CGeneTech (Suzhou, China) Co., Ltd.	FUSED RING COMPOUND AS DUAL FGFR AND VEGFR INHIBITOR
US11753413B2 (en)	2020-06-19	2023-09-12	Incyte Corporation	Substituted pyrrolo[2,1-f][1,2,4]triazine compounds as JAK2 V617F inhibitors
US11691971B2 (en)	2020-06-19	2023-07-04	Incyte Corporation	Naphthyridinone compounds as JAK2 V617F inhibitors
RS66978B1 (sr)	2020-07-02	2025-07-31	Incyte Corp	Triciklična jedinjenja uree kao inhibitori jak2 v617f
WO2022006456A1 (en)	2020-07-02	2022-01-06	Incyte Corporation	Tricyclic pyridone compounds as jak2 v617f inhibitors
US11661422B2 (en)	2020-08-27	2023-05-30	Incyte Corporation	Tricyclic urea compounds as JAK2 V617F inhibitors
CN116600812A (zh) *	2020-12-21	2023-08-15	拜奥克里斯特制药公司	口服alk2抑制剂的给药方案
US11919908B2 (en)	2020-12-21	2024-03-05	Incyte Corporation	Substituted pyrrolo[2,3-d]pyrimidine compounds as JAK2 V617F inhibitors
KR102612407B1 (ko) *	2021-01-14	2023-12-11	환인제약 주식회사	Ｂｍｓ－７５４８０７ 화합물을 유효성분으로 포함하는 신경염증성 질환의 예방 또는 치료용 약학적 조성물
WO2022182839A1 (en)	2021-02-25	2022-09-01	Incyte Corporation	Spirocyclic lactams as jak2 v617f inhibitors
CN112679407B (zh) *	2021-03-17	2021-06-04	南京桦冠生物技术有限公司	一种手性5-取代脯氨酸类化合物的制备方法
MX2024003795A (es) *	2021-09-29	2024-06-03	Repare Therapeutics Inc	Compuestos de n-(5-sustituido-[(1,3,4-tiadiazolil) o (tiazolil)])(sustituido)carboxamida y uso de estos para inhibir la polimerasa theta humana.
KR20240163688A (ko)	2022-03-17	2024-11-19	인사이트 코포레이션	Jak2 v617f 억제제로서의 삼환계 우레아 화합물
AU2023249795A1 (en)	2022-04-08	2024-10-17	Shy Therapeutics, Llc	Compounds that interact with ras superfamily proteins for treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
CN120344522A (zh) *	2022-09-29	2025-07-18	修复治疗公司	N-(5-取代的-[(1,3,4-噻二唑基)或(1,3-噻唑基)](取代的)甲酰胺化合物、药物组合物以及制备酰胺化合物的方法及其用途
CN116178358B (zh) *	2022-11-04	2024-04-19	济南大学	一种靶向c-Src激酶SH3结构域的化合物及其应用
WO2025014773A1 (en)	2023-07-07	2025-01-16	Viridian Therapeutics, Inc.	Methods of treating chronic thyroid eye disease

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2373990C (en)	1999-05-21	2007-05-08	Bristol-Myers Squibb Company	Pyrrolotriazine inhibitors of kinases
US6982265B1 (en)	1999-05-21	2006-01-03	Bristol Myers Squibb Company	Pyrrolotriazine inhibitors of kinases
US6670357B2 (en)	2000-11-17	2003-12-30	Bristol-Myers Squibb Company	Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors
TWI329112B (en) *	2002-07-19	2010-08-21	Bristol Myers Squibb Co	Novel inhibitors of kinases
AU2003265349A1 (en) *	2002-08-02	2004-02-23	Bristol-Myers Squibb Company	Pyrrolotriazine kinase inhibitors
DE602005023333D1 (de)	2004-10-15	2010-10-14	Takeda Pharmaceutical	Kinaseinhibitoren
JP5185930B2 (ja) *	2006-07-07	2013-04-17	ブリストル−マイヤーズスクイブカンパニー	ピロロトリアジンキナーゼ阻害剤
US7531539B2 (en)	2006-08-09	2009-05-12	Bristol-Myers Squibb Company	Pyrrolotriazine kinase inhibitors
ES2393410T3 (es)	2006-08-09	2012-12-21	Bristol-Myers Squibb Company	Pirrolotriazinas inhibidoras de quinasas
WO2008057994A2 (en)	2006-11-03	2008-05-15	Bristol-Myers Squibb Company	Pyrrolotriazine kinase inhibitors

2007
- 2007-07-03 JP JP2009519588A patent/JP5185930B2/ja not_active Expired - Fee Related
- 2007-07-03 HR HRP20140688TT patent/HRP20140688T1/hr unknown
- 2007-07-03 EA EA200900152A patent/EA018322B1/ru not_active IP Right Cessation
- 2007-07-03 EP EP07799265.9A patent/EP2041138B1/en active Active
- 2007-07-03 CN CN2007800327558A patent/CN101511835B/zh not_active Expired - Fee Related
- 2007-07-03 CA CA2657594A patent/CA2657594C/en not_active Expired - Fee Related
- 2007-07-03 KR KR1020097002487A patent/KR101443400B1/ko not_active Expired - Fee Related
- 2007-07-03 PT PT77992659T patent/PT2041138E/pt unknown
- 2007-07-03 DK DK07799265.9T patent/DK2041138T3/da active
- 2007-07-03 AU AU2007269163A patent/AU2007269163B2/en not_active Ceased
- 2007-07-03 NZ NZ574189A patent/NZ574189A/en unknown
- 2007-07-03 ES ES07799265.9T patent/ES2493566T3/es active Active
- 2007-07-03 WO PCT/US2007/072697 patent/WO2008005956A2/en not_active Ceased
- 2007-07-03 BR BRPI0714359-1A patent/BRPI0714359A2/pt active Search and Examination
- 2007-07-03 MX MX2008016517A patent/MX2008016517A/es active IP Right Grant
- 2007-07-03 SI SI200731488T patent/SI2041138T1/sl unknown
- 2007-07-03 PL PL07799265T patent/PL2041138T3/pl unknown
- 2007-07-05 US US11/773,466 patent/US7534792B2/en active Active
- 2007-07-05 PE PE2007000874A patent/PE20080677A1/es active IP Right Grant
- 2007-07-06 CL CL2007001995A patent/CL2007001995A1/es unknown
- 2007-07-06 TW TW096124588A patent/TWI393722B/zh not_active IP Right Cessation
- 2007-07-10 AR ARP070103070A patent/AR061873A1/es not_active Application Discontinuation
2008
- 2008-12-18 IL IL196033A patent/IL196033A0/en active IP Right Grant
2009
- 2009-01-05 NO NO20090025A patent/NO342385B1/no not_active IP Right Cessation
- 2009-01-06 CO CO09000765A patent/CO6220940A2/es active IP Right Grant
- 2009-01-06 ZA ZA200900109A patent/ZA200900109B/xx unknown
- 2009-03-26 US US12/411,724 patent/US7879855B2/en active Active
2011
- 2011-01-28 US US13/015,687 patent/US8263765B2/en active Active
2012
- 2012-08-07 US US13/568,750 patent/US8592579B2/en active Active

Also Published As

Publication number	Publication date
WO2008005956A2 (en)	2008-01-10
US20090239838A1 (en)	2009-09-24
CA2657594A1 (en)	2008-01-10
CN101511835B (zh)	2013-11-27
CN101511835A (zh)	2009-08-19
ZA200900109B (en)	2010-03-31
TW200813059A (en)	2008-03-16
AU2007269163A1 (en)	2008-01-10
PE20080677A1 (es)	2008-06-26
US7534792B2 (en)	2009-05-19
AR061873A1 (es)	2008-09-24
AU2007269163B2 (en)	2011-07-28
NO342385B1 (no)	2018-05-14
EA018322B1 (ru)	2013-07-30
EP2041138B1 (en)	2014-06-25
MX2008016517A (es)	2009-01-19
US20120302747A1 (en)	2012-11-29
TWI393722B (zh)	2013-04-21
US7879855B2 (en)	2011-02-01
NZ574189A (en)	2011-03-31
ES2493566T3 (es)	2014-09-12
HRP20140688T1 (hr)	2014-10-24
KR101443400B1 (ko)	2014-10-02
EP2041138A2 (en)	2009-04-01
CL2007001995A1 (es)	2008-01-25
PL2041138T3 (pl)	2014-11-28
CA2657594C (en)	2012-01-17
US8263765B2 (en)	2012-09-11
WO2008005956A3 (en)	2008-03-06
US8592579B2 (en)	2013-11-26
IL196033A0 (en)	2009-09-01
US20080009497A1 (en)	2008-01-10
NO20090025L (no)	2009-02-02
CO6220940A2 (es)	2010-11-19
DK2041138T3 (da)	2014-08-11
JP2009542814A (ja)	2009-12-03
JP5185930B2 (ja)	2013-04-17
PT2041138E (pt)	2014-10-07
EA200900152A1 (ru)	2009-06-30
BRPI0714359A2 (pt)	2013-02-26
KR20090027764A (ko)	2009-03-17
US20110124623A1 (en)	2011-05-26

Publication	Publication Date	Title
IL284889A (en)	2021-08-31	Imidazotriazines and imidazopyrimidines as kinase inhibitors
ZA200900109B (en)	2010-03-31	Pyrrolotriazine kinase inhibitors
IL197381A0 (en)	2009-12-24	Kinase inhibitor
IL190078A0 (en)	2008-08-07	Kinase inhibitors
PL2079727T3 (pl)	2016-08-31	Inhibitory kinazy
ZA200606683B (en)	2008-01-30	Pyrazolotriazines as kinase inhibitors
EP1794137A4 (en)	2009-12-02	SPECIFIC KINASE INHIBITORS
EP1761268A4 (en)	2009-07-08	KINASE INHIBITORS BASED ON PYRROLOTRIAZINE
IL183276A0 (en)	2007-10-31	Kinase inhibitors
EP2166857A4 (en)	2011-03-30	KINASE INHIBITOR COMPOUNDS
SI1943243T1 (sl)	2011-04-29	Inhibotorji kinaz
ZA200607648B (en)	2008-06-25	Kinase inhibitors
EP1968581A4 (en)	2009-05-27	TETRACYCLIC KINASE INHIBITORS
EP2036893A4 (en)	2011-04-13	ABL Kinase Inhibitor
ZA200908943B (en)	2010-08-25	Pyrazolopyrimidinone kinase inhibitor
IL197981A0 (en)	2009-12-24	Kinase inhibitors
GB0608854D0 (en)	2006-06-14	P13 kinase inhibitors
ZA200803287B (en)	2009-10-28	Kinase inhibitors
IL189985A0 (en)	2008-08-07	Kinase inhibitors
GB0622367D0 (en)	2006-12-20	Phosphodiesterase inhibitors
HK1120508A (en)	2009-04-03	Kinase inhibitors
EP1940411A4 (en)	2008-10-29	MACROHETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS
GB0621719D0 (en)	2006-12-13	Ikk- serine-threonine protein kinase inhibitors